Robert W. Baird reiterated their buy rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note released on Friday, January 19th, The Fly reports. The brokerage currently has a $144.00 price objective on the biotechnology company’s stock, up from their prior price objective of $81.00.
Several other research analysts also recently commented on the company. Zacks Investment Research downgraded AnaptysBio from a buy rating to a hold rating in a research note on Tuesday, January 2nd. Royal Bank of Canada raised their target price on AnaptysBio to $108.00 and gave the stock an outperform rating in a research note on Monday, December 18th. SunTrust Banks initiated coverage on AnaptysBio in a research report on Wednesday, November 15th. They set a buy rating and a $115.00 price target for the company. Jefferies Group initiated coverage on AnaptysBio in a research report on Thursday, November 9th. They set a buy rating and a $101.00 price target for the company. Finally, Wedbush reiterated a positive rating and set a $82.00 price target (up previously from $75.00) on shares of AnaptysBio in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. AnaptysBio has an average rating of Buy and an average price target of $101.89.
AnaptysBio (NASDAQ:ANAB) traded up $2.96 during mid-day trading on Friday, hitting $107.29. The stock had a trading volume of 241,172 shares, compared to its average volume of 312,605. AnaptysBio has a 12 month low of $18.15 and a 12 month high of $126.23. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.77 and a quick ratio of 10.77. The company has a market cap of $2,500.00 and a P/E ratio of -71.05.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. OppenheimerFunds Inc. purchased a new position in AnaptysBio in the 4th quarter worth approximately $106,701,000. Brown Advisory Inc. purchased a new position in AnaptysBio in the 4th quarter worth approximately $6,549,000. American International Group Inc. increased its stake in AnaptysBio by 50.8% in the 4th quarter. American International Group Inc. now owns 12,025 shares of the biotechnology company’s stock worth $1,211,000 after purchasing an additional 4,053 shares during the period. Virtus Fund Advisers LLC purchased a new position in AnaptysBio in the 4th quarter worth approximately $387,000. Finally, UBS Asset Management Americas Inc. purchased a new position in AnaptysBio in the 4th quarter worth approximately $7,189,000. 76.23% of the stock is currently owned by institutional investors.
WARNING: “AnaptysBio (ANAB) Stock Rating Reaffirmed by Robert W. Baird” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/12/anaptysbio-anab-stock-rating-reaffirmed-by-robert-w-baird.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.